AP2015008203A0 - Heteroaromatic compounds as bruton's tyrosine kinase (BTK) inhibitors - Google Patents

Heteroaromatic compounds as bruton's tyrosine kinase (BTK) inhibitors

Info

Publication number
AP2015008203A0
AP2015008203A0 AP2015008203A AP2015008203A AP2015008203A0 AP 2015008203 A0 AP2015008203 A0 AP 2015008203A0 AP 2015008203 A AP2015008203 A AP 2015008203A AP 2015008203 A AP2015008203 A AP 2015008203A AP 2015008203 A0 AP2015008203 A0 AP 2015008203A0
Authority
AP
ARIPO
Prior art keywords
bruton
btk
inhibitors
tyrosine kinase
heteroaromatic compounds
Prior art date
Application number
AP2015008203A
Other languages
English (en)
Inventor
Renee M Zindell
Todd Bosanac
Darren Todd Disalvo
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49029216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2015008203(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2015008203A0 publication Critical patent/AP2015008203A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AP2015008203A 2012-08-10 2013-08-08 Heteroaromatic compounds as bruton's tyrosine kinase (BTK) inhibitors AP2015008203A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261681684P 2012-08-10 2012-08-10
PCT/US2013/054096 WO2014025976A1 (en) 2012-08-10 2013-08-08 Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors

Publications (1)

Publication Number Publication Date
AP2015008203A0 true AP2015008203A0 (en) 2015-01-31

Family

ID=49029216

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008203A AP2015008203A0 (en) 2012-08-10 2013-08-08 Heteroaromatic compounds as bruton's tyrosine kinase (BTK) inhibitors

Country Status (24)

Country Link
US (5) US20140045813A1 (enExample)
EP (1) EP2882741B1 (enExample)
JP (1) JP6348492B2 (enExample)
KR (1) KR20150040292A (enExample)
CN (1) CN104603124B (enExample)
AP (1) AP2015008203A0 (enExample)
AU (1) AU2013299557B2 (enExample)
BR (1) BR112015002590A2 (enExample)
CA (1) CA2881519A1 (enExample)
CL (1) CL2015000256A1 (enExample)
EA (1) EA029210B1 (enExample)
EC (1) ECSP15008851A (enExample)
GE (1) GEP201706748B (enExample)
IL (1) IL236495A0 (enExample)
IN (1) IN2015DN00524A (enExample)
MA (1) MA37830B1 (enExample)
MX (1) MX2015001802A (enExample)
NZ (1) NZ703607A (enExample)
PE (1) PE20150756A1 (enExample)
PH (1) PH12015500294B1 (enExample)
SA (1) SA515360007B1 (enExample)
SG (1) SG11201500499TA (enExample)
TN (1) TN2015000029A1 (enExample)
WO (1) WO2014025976A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201500499TA (en) 2012-08-10 2015-03-30 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
EA201500393A1 (ru) 2012-11-02 2016-05-31 Пфайзер Инк. Ингибиторы тирозинкиназы брутона
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
WO2014151620A1 (en) * 2013-03-14 2014-09-25 Boehringer Ingelheim International Gmbh 5-thiazolecarboxamide dervatives and their use as btk inhibitors
AU2014230935A1 (en) * 2013-03-15 2015-09-03 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
US8940893B2 (en) 2013-03-15 2015-01-27 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
SI3052476T1 (sl) * 2013-09-30 2020-12-31 Guangzhou Innocare Pharma Tech Co., Ltd. Substituirani nikotinimidni inhibitorji BTK in njihova priprava in uporaba pri zdravljenju raka, vnetja in avtoimunske bolezni
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
JP6486954B2 (ja) * 2014-01-29 2019-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのピラゾール化合物
WO2015185998A2 (en) * 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
CN108368086B (zh) 2015-12-16 2021-01-08 勃林格殷格翰国际有限公司 可用于治疗自身免疫疾病的二吡唑基衍生物
MA49809A1 (fr) 2015-12-16 2021-08-31 Loxo Oncology Inc Composés utilisés comme inhibiteurs de kinase
CN105646318A (zh) * 2015-12-30 2016-06-08 武汉药明康德新药开发有限公司 一种2-叔丁氧羰基-5-氮杂螺环[3.3]庚烷-6-羧酸的合成方法
JP6916185B2 (ja) 2016-01-13 2021-08-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのイソキノロン類
CN107226805A (zh) * 2016-03-24 2017-10-03 北京天诚医药科技有限公司 芳香族酰胺类衍生物、其制备方法及其在医药上的应用
AU2017311664C1 (en) 2016-08-15 2025-05-22 Novartis Ag Regimens and methods of treating multiple sclerosis using ofatumumab
CN107759602B (zh) * 2016-08-17 2020-04-21 中国科学院上海药物研究所 含有共轭联烯结构的化合物、其药物组合物和用途
JOP20190113A1 (ar) * 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
US20200369611A1 (en) * 2017-08-01 2020-11-26 Boehringer Ingelheim International Gmbh Intermediate compounds and methods
TWI767148B (zh) * 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
CN119350306A (zh) 2018-12-13 2025-01-24 英特维特国际股份有限公司 1-[(3r,4s)-4-氰基四氢吡喃-3-基]-3-[(2-氟-6-甲氧基-4-吡啶基)氨基]吡唑-4-甲酰胺制备方法
KR102200032B1 (ko) * 2019-03-13 2021-01-08 전남대학교산학협력단 호흡기 질환의 예방 또는 치료용 조성물
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
JP7475370B2 (ja) * 2019-05-10 2024-04-26 河南知微生物医薬有限公司 ブルトン型チロシンキナーゼ阻害剤としての置換されている１－アミノ－１ｈ－イミダゾール－５－カルボキサミド
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021294035A1 (en) * 2020-06-19 2023-02-16 Anaxis Pharma Pty Ltd Sulphonamide compounds
CN114573586B (zh) * 2020-11-28 2023-11-03 杭州和正医药有限公司 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors
AU2022409472A1 (en) 2021-12-14 2024-06-27 Crossfire Oncology Holding B.V. Macrocyclic btk inhibitors
CN116554102B (zh) * 2022-01-28 2025-10-03 深圳海博为药业有限公司 一种作为btk抑制剂的化合物及其制备方法和应用
HRP20251427T1 (hr) * 2022-08-04 2025-12-19 Nxera Pharma Uk Limited Oblici citratne soli agonista muskarinskih receptora

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
EA007933B1 (ru) * 2001-08-13 2007-02-27 Янссен Фармацевтика Н.В. 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность
US7307097B2 (en) 2001-09-27 2007-12-11 Smithkline Beechman Corporation Chemical compounds
FR2881426B1 (fr) * 2005-02-03 2007-03-30 Aventis Pharma Sa Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
EP2007732B1 (en) * 2006-04-11 2011-11-23 Vertex Pharmaceuticals, Inc. Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
AR063706A1 (es) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
PL2526933T3 (pl) * 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
EP2139487B1 (en) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
MX2010013191A (es) 2008-06-24 2010-12-17 Hoffmann La Roche Nuevas piridin-3-onas y piridazin-3-onas sustituidas.
PL2310528T3 (pl) 2008-07-29 2014-04-30 Univ Liege Marker genetyczny do testowania brachyspiny i płodności u bydła
GB0820819D0 (en) * 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
JP2012516329A (ja) * 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
SG181643A1 (en) 2009-12-17 2012-07-30 Merck Patent Gmbh Inhibitors of sphingosine kinase
EP2578585B1 (en) 2010-05-31 2016-07-20 ONO Pharmaceutical Co., Ltd. Purinone derivative as btk kinase inhibitor
WO2012021615A1 (en) * 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
SG194728A1 (en) 2011-05-17 2013-12-30 Hoffmann La Roche Inhibitors of bruton's tyrosine kinase
TW201311669A (zh) 2011-08-17 2013-03-16 Hoffmann La Roche 布魯頓氏酪胺酸激酶（ｂｒｕｔｏｎ’ｓ ｔｙｒｏｓｉｎｅ ｋｉｎａｓｅ）之抑制劑
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP5985658B2 (ja) 2012-01-31 2016-09-06 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． ブルトンチロシンキナーゼ阻害薬としての環状分子
IN2012CH01573A (enExample) 2012-04-20 2015-07-10 Advinus Therapeutics Ltd
SG11201500499TA (en) 2012-08-10 2015-03-30 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
CN104619696A (zh) 2012-09-13 2015-05-13 弗·哈夫曼-拉罗切有限公司 布鲁顿氏酪氨酸激酶抑制剂
EA201500393A1 (ru) 2012-11-02 2016-05-31 Пфайзер Инк. Ингибиторы тирозинкиназы брутона
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US8940893B2 (en) 2013-03-15 2015-01-27 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
RU2016112314A (ru) 2013-09-03 2017-10-05 Карна Байосайенсиз, Инк. Новое 2,6-диаминопиримидиновое производное
JP6486954B2 (ja) 2014-01-29 2019-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのピラゾール化合物
CN108368086B (zh) 2015-12-16 2021-01-08 勃林格殷格翰国际有限公司 可用于治疗自身免疫疾病的二吡唑基衍生物

Also Published As

Publication number Publication date
TN2015000029A1 (en) 2016-06-29
MA37830B1 (fr) 2018-09-28
AU2013299557A1 (en) 2015-01-29
HK1210161A1 (en) 2016-04-15
IN2015DN00524A (enExample) 2015-06-26
EP2882741B1 (en) 2018-10-24
AU2013299557B2 (en) 2017-06-22
US10138229B2 (en) 2018-11-27
CN104603124A (zh) 2015-05-06
KR20150040292A (ko) 2015-04-14
JP2015524480A (ja) 2015-08-24
WO2014025976A1 (en) 2014-02-13
CA2881519A1 (en) 2014-02-13
NZ703607A (en) 2018-02-23
US20160031872A1 (en) 2016-02-04
EP2882741A1 (en) 2015-06-17
SA515360007B1 (ar) 2016-09-04
PH12015500294A1 (en) 2015-04-20
US20190112302A1 (en) 2019-04-18
US20140045813A1 (en) 2014-02-13
IL236495A0 (en) 2015-02-26
EA029210B1 (ru) 2018-02-28
GEP201706748B (en) 2017-10-10
ECSP15008851A (es) 2015-12-31
US10875852B2 (en) 2020-12-29
BR112015002590A2 (pt) 2019-08-06
PH12015500294B1 (en) 2015-04-20
SG11201500499TA (en) 2015-03-30
JP6348492B2 (ja) 2018-06-27
CN104603124B (zh) 2018-04-17
PE20150756A1 (es) 2015-06-03
MA20150290A1 (fr) 2015-08-31
US20180086748A1 (en) 2018-03-29
MX2015001802A (es) 2015-05-07
CL2015000256A1 (es) 2015-07-03
EA201500207A1 (ru) 2015-08-31
US20170320867A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
IL236495A0 (en) Heteroaromatic compounds as proton tyrosine kinase inhibitors
ZA202105174B (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
IL272622A (en) Use of proton tyrosine kinase inhibitors
IL238571A0 (en) Broton tyrosine kinase inhibitors, preparations containing them and their uses
EP2925740A4 (en) INHIBITORS OF BRUTON TYROSINE KINASE
EP2809673A4 (en) CYCLIC MOLECULES AS AN INHIBITORS OF BRUTON TYROSINE KINASE
IL244492A0 (en) Broton tyrosine kinase inhibitors
IL248546B (en) A multi-fluorinated compound as an inhibitor of proton tyrosine kinase
ZA201400012B (en) Inhibitors of bruton's tyrosine kinase
ZA201308397B (en) Inhibitors of bruton's tyrosine kinase
IL238728A0 (en) Pyrrolopyrimidine compounds as kinase inhibitors
ZA201400739B (en) Inhibitors of bruton's tyrosine kinase
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
ZA201406688B (en) Serine, threonine kinase inhibitors
IL235938A0 (en) Pyrimidinyls are tyrosine kinase inhibitors
ZA201409256B (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
BR112015005361A2 (pt) inibidores de tirosina quinase de bruton
ZA201406777B (en) 3,5-diaminopyrazole kinase inhibitors
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
AP2015008532A0 (en) Syk kinase inhibitors as treatment for malaria
GB201209458D0 (en) Novel compounds and their use as kinase inhibitors
GB201206048D0 (en) Novel compounds and their use as kinase inhibitors